Chitinase Inhibitors for Asthma

OCR Number: OCR 1181

Description:

- Chitinases are over-expressed in the lungs of patients with asthma, and in mouse models of asthma (Figure 1).
- Treatment of these mice with anti-chitinase antibodies or small molecule inhibitors markedly decreased asthma symptoms (Figure 2).
- YKL-40, a member of this protein family, is a key regulator of cytokine signaling, inflammation, apoptosis, angiogenesis, and tissue remodeling.
- Potential indications include asthma/COPD, inflammation, atherosclerosis, and cancer.

Stage of Development: Extensive in vivo studies have been done.

IP Status: Yale has extensive IP portfolio in this area, including exclusive access to large panel of monoclonal antibodies.

Published/Issued Patents: U.S. Patent No. 7,214,373,

Published/Issued Patents: U.S. Patent No. 8,679,503
